Neovasc Inc (NVCN) Receives a Buy from Leerink Partners


In a report released today, Danielle Antalffy from Leerink Partners maintained a Buy rating on Neovasc Inc (NASDAQ: NVCN), with a price target of $3. The company’s shares closed yesterday at $2.25, close to its 52-week low of $2.14.

According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 24.3% and a 66.7% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Insulet Corp, and Medtronic.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neovasc Inc with a $10 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $175.50 and a one-year low of $2.14. Currently, Neovasc Inc has an average volume of 13.1M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neovasc, Inc. engages in the development, manufacture, and marketing of medical devices for the cardiovascular marketplace. Its products includes Neovast Tiara and Neovasc Reducer. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts